{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:55:13Z","timestamp":1788897313289,"version":"build-2803163510"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK092759-01"],"award-info":[{"award-number":["DK092759-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM106391"],"award-info":[{"award-number":["P30GM106391"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008955","name":"Maine Medical Center Research Institute","doi-asserted-by":"publisher","award":["Start-Up funds"],"award-info":[{"award-number":["Start-Up funds"]}],"id":[{"id":"10.13039\/100008955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["Project Grant RG 16-03"],"award-info":[{"award-number":["Project Grant RG 16-03"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00223-016-0162-2","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T19:27:08Z","timestamp":1466882828000},"page":"433-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Adipose, Bone, and Myeloma: Contributions from the Microenvironment"],"prefix":"10.1007","volume":"100","author":[{"given":"Michelle M.","family":"McDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Fairfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyne","family":"Falank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-6481","authenticated-orcid":false,"given":"Michaela R.","family":"Reagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,24]]},"reference":[{"key":"162_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/14728210802676278","volume":"14","author":"K Podar","year":"2009","unstructured":"Podar K, Tai Y-T, Hideshima T et al (2009) Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs 14:99\u2013127","journal-title":"Expert Opin Emerg Drugs"},{"key":"162_CR2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1864","author":"R Noopur","year":"2015","unstructured":"Noopur R, Vescio R, Montgomery CW et al (2015) Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK study. Clin Cancer Res. doi:\n                    10.1158\/1078-0432.CCR-15-1864","journal-title":"Clin Cancer Res"},{"key":"162_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.160","author":"MR Reagan","year":"2015","unstructured":"Reagan MR, Rosen CJ (2015) Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nat Rev Rheumatol. doi:\n                    10.1038\/nrrheum.2015.160","journal-title":"Nat Rev Rheumatol"},{"key":"162_CR4","doi-asserted-by":"publisher","first-page":"e0138189","DOI":"10.1371\/journal.pone.0138189","volume":"10","author":"J Xiong","year":"2015","unstructured":"Xiong J, Piemontese M, Onal M et al (2015) Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. PLoS One 10:e0138189. doi:\n                    10.1371\/journal.pone.0138189","journal-title":"PLoS One"},{"key":"162_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ajpath.2013.11.022","volume":"184","author":"HB Kristensen","year":"2014","unstructured":"Kristensen HB, Andersen TL, Marcussen N et al (2014) Osteoblast recruitment routes in human cancellous bone remodeling. Am J Pathol 184:778\u2013789. doi:\n                    10.1016\/j.ajpath.2013.11.022","journal-title":"Am J Pathol"},{"key":"162_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jbmr.320","volume":"26","author":"LF Bonewald","year":"2011","unstructured":"Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229\u2013238. doi:\n                    10.1002\/jbmr.320","journal-title":"J Bone Miner Res"},{"key":"162_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:179\u2013192. doi:\n                    10.1038\/nm.3074","journal-title":"Nat Med"},{"key":"162_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","volume":"76","author":"J Delgado-Calle","year":"2016","unstructured":"Delgado-Calle J, Anderson J, Cregor MD et al (2016) Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res 76:1089\u20131100. doi:\n                    10.1158\/0008-5472.CAN-15-1703","journal-title":"Cancer Res"},{"key":"162_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1615\/CritRevEukarGeneExpr.v19.i2.20","volume":"19","author":"CJ Rosen","year":"2009","unstructured":"Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM (2009) Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot Gene Expr 19:109\u2013124. doi:\n                    10.1016\/j.bbi.2008.05.010","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"162_CR10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1210\/jc.2012-3634","volume":"98","author":"PK Fazeli","year":"2013","unstructured":"Fazeli PK, Horowitz MC, MacDougald OA et al (2013) Marrow fat and bone-new perspectives. J Clin Endocrinol Metab 98:935\u2013945. doi:\n                    10.1210\/jc.2012-3634","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/nyas.12327","volume":"1311","author":"EL Scheller","year":"2014","unstructured":"Scheller EL, Rosen CJ (2014) What\u2019s the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health. Ann N Y Acad Sci 1311:14\u201330. doi:\n                    10.1111\/nyas.12327","journal-title":"Ann N Y Acad Sci"},{"key":"162_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nature08099","volume":"460","author":"O Naveiras","year":"2009","unstructured":"Naveiras O, Nardi V, Wenzel PL et al (2009) Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460:259\u2013263. doi:\n                    10.1038\/nature08099","journal-title":"Nature"},{"key":"162_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.cmet.2014.06.003","volume":"20","author":"WP Cawthorn","year":"2014","unstructured":"Cawthorn WP, Scheller EL, Learman BS et al (2014) Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab 20:368\u2013375. doi:\n                    10.1016\/j.cmet.2014.06.003","journal-title":"Cell Metab"},{"key":"162_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.stem.2014.06.008","volume":"15","author":"BO Zhou","year":"2014","unstructured":"Zhou BO, Yue R, Murphy MM et al (2014) Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15:154\u2013168. doi:\n                    10.1016\/j.stem.2014.06.008","journal-title":"Cell Stem Cell"},{"key":"162_CR15","doi-asserted-by":"publisher","first-page":"e71318","DOI":"10.1371\/journal.pone.0071318","volume":"8","author":"Y Liu","year":"2013","unstructured":"Liu Y, Strecker S, Wang L et al (2013) Osterix-cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. PLoS One 8:e71318. doi:\n                    10.1371\/journal.pone.0071318","journal-title":"PLoS One"},{"key":"162_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2014.12.002","volume":"160","author":"CKF Chan","year":"2015","unstructured":"Chan CKF, Seo EY, Chen JY et al (2015) Identification and specification of the mouse skeletal stem cell. Cell 160:285\u2013298. doi:\n                    10.1016\/j.cell.2014.12.002","journal-title":"Cell"},{"key":"162_CR17","doi-asserted-by":"publisher","first-page":"e99137","DOI":"10.1371\/journal.pone.0099137","volume":"9","author":"B Gao","year":"2014","unstructured":"Gao B, Huang Q, Lin Y-S et al (2014) Dose-dependent effect of estrogen suppresses the osteo-adipogenic transdifferentiation of osteoblasts via canonical Wnt signaling pathway. PLoS One 9:e99137. doi:\n                    10.1371\/journal.pone.0099137","journal-title":"PLoS One"},{"key":"162_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s002239900626","volume":"64","author":"N Miyakoshi","year":"1999","unstructured":"Miyakoshi N, Sato K, Abe T et al (1999) Histomorphometric evaluation of the effects of ovariectomy on bone turnover in rat caudal vertebrae. Calcif Tissue Int 64:318\u2013324","journal-title":"Calcif Tissue Int"},{"key":"162_CR19","doi-asserted-by":"publisher","first-page":"e0129764","DOI":"10.1371\/journal.pone.0129764","volume":"10","author":"FJA de Paula","year":"2015","unstructured":"de Paula FJA, de Ara\u00fajo IM, Carvalho AL et al (2015) The relationship of fat distribution and insulin resistance with lumbar spine bone mass in women. PLoS One 10:e0129764. doi:\n                    10.1371\/journal.pone.0129764","journal-title":"PLoS One"},{"key":"162_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.bone.2014.07.024","volume":"68","author":"N Bonnet","year":"2014","unstructured":"Bonnet N, Somm E, Rosen CJ (2014) Diet and gene interactions influence the skeletal response to polyunsaturated fatty acids. Bone 68:100\u2013107. doi:\n                    10.1016\/j.bone.2014.07.024","journal-title":"Bone"},{"key":"162_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24954","author":"CR Doucette","year":"2015","unstructured":"Doucette CR, Horowitz MC, Berry R et al (2015) A high fat diet increases bone marrow adipose tissue (MAT) but does not alter trabecular or cortical bone mass in C57BL\/6J mice. J Cell Physiol. doi:\n                    10.1002\/jcp.24954","journal-title":"J Cell Physiol"},{"key":"162_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5312\/wjo.v5.i3.242","volume":"5","author":"G Colaianni","year":"2014","unstructured":"Colaianni G, Brunetti G, Faienza MF et al (2014) Osteoporosis and obesity: role of Wnt pathway in human and murine models. World J Orthop 5:242\u2013246. doi:\n                    10.5312\/wjo.v5.i3.242","journal-title":"World J Orthop"},{"key":"162_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.abb.2014.06.010","volume":"561","author":"B Lecka-Czernik","year":"2014","unstructured":"Lecka-Czernik B, Stechschulte LA (2014) Bone and fat: a relationship of different shades. Arch Biochem Biophys 561:124\u2013129. doi:\n                    10.1016\/j.abb.2014.06.010","journal-title":"Arch Biochem Biophys"},{"key":"162_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/8756-3282(91)90011-7","volume":"12","author":"RB Martin","year":"1991","unstructured":"Martin RB, Zissimos SL (1991) Relationships between marrow fat and bone turnover in ovariectomized and intact rats. Bone 12:123\u2013131","journal-title":"Bone"},{"key":"162_CR25","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1210\/en.2015-1213","volume":"156","author":"M Styner","year":"2015","unstructured":"Styner M, Pagnotti GM, Galior K et al (2015) Exercise regulation of marrow fat in the setting of PPAR\u03b3 agonist treatment in female C57BL\/6 mice. Endocrinology 156:2753\u20132761. doi:\n                    10.1210\/en.2015-1213","journal-title":"Endocrinology"},{"key":"162_CR26","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/jcp.25201","volume":"231","author":"D Xuan","year":"2016","unstructured":"Xuan D, Han Q, Tu Q et al (2016) Epigenetic modulation in periodontitis: interaction of adiponectin and JMJD3-IRF4 axis in macrophages. J Cell Physiol 231:1090\u20131096. doi:\n                    10.1002\/jcp.25201","journal-title":"J Cell Physiol"},{"key":"162_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/nrendo.2014.169","volume":"10","author":"BJ Adler","year":"2014","unstructured":"Adler BJ, Kaushansky K, Rubin CT (2014) Obesity-driven disruption of haematopoiesis and the bone marrow niche. Nat Rev Endocrinol 10:737\u2013748. doi:\n                    10.1038\/nrendo.2014.169","journal-title":"Nat Rev Endocrinol"},{"key":"162_CR28","doi-asserted-by":"publisher","DOI":"10.1096\/fj.15-278994","author":"KM Gavin","year":"2015","unstructured":"Gavin KM, Gutman JA, Kohrt WM et al (2015) De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissue. FASEB J. doi:\n                    10.1096\/fj.15-278994","journal-title":"FASEB J"},{"key":"162_CR29","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1210\/jc.2011-2605","volume":"97","author":"W Shen","year":"2012","unstructured":"Shen W, Scherzer R, Gantz M et al (2012) Relationship between MRI-measured bone marrow adipose tissue and hip and spine bone mineral density in African-American and Caucasian participants: the CARDIA study. J Clin Endocrinol Metab 97:1337\u20131346. doi:\n                    10.1210\/jc.2011-2605","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jocd.2013.02.009","volume":"17","author":"W Shen","year":"2014","unstructured":"Shen W, Velasquez G, Chen J et al (2014) Comparison of the relationship between bone marrow adipose tissue and volumetric bone mineral density in children and adults. J Clin Densitom 17:163\u2013169. doi:\n                    10.1016\/j.jocd.2013.02.009","journal-title":"J Clin Densitom"},{"key":"162_CR31","doi-asserted-by":"publisher","first-page":"7808","DOI":"10.1038\/ncomms8808","volume":"6","author":"EL Scheller","year":"2015","unstructured":"Scheller EL, Doucette CR, Learman BS et al (2015) Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. Nat Commun 6:7808. doi:\n                    10.1038\/ncomms8808","journal-title":"Nat Commun"},{"key":"162_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315\u2013317. doi:\n                    10.1080\/14653240600855905","journal-title":"Cytotherapy"},{"key":"162_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1749-6632.2012.06551.x","volume":"1266","author":"K Sivasubramaniyan","year":"2012","unstructured":"Sivasubramaniyan K, Lehnen D, Ghazanfari R et al (2012) Phenotypic and functional heterogeneity of human bone marrow- and amnion-derived MSC subsets. Ann N Y Acad Sci 1266:94\u2013106. doi:\n                    10.1111\/j.1749-6632.2012.06551.x","journal-title":"Ann N Y Acad Sci"},{"key":"162_CR34","doi-asserted-by":"publisher","first-page":"762695","DOI":"10.1155\/2014\/762695","volume":"2014","author":"D Galli","year":"2014","unstructured":"Galli D, Vitale M, Vaccarezza M (2014) Bone marrow-derived mesenchymal cell differentiation toward myogenic lineages: facts and perspectives. Biomed Res Int 2014:762695. doi:\n                    10.1155\/2014\/762695","journal-title":"Biomed Res Int"},{"key":"162_CR35","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1089\/scd.2015.0112","volume":"24","author":"RD Moirangthem","year":"2015","unstructured":"Moirangthem RD, Singh S, Adsul A et al (2015) Hypoxic niche-mediated regeneration of hematopoiesis in the engraftment window is dominantly affected by oxygen tension in the milieu. Stem Cells Dev 24:2423\u20132436. doi:\n                    10.1089\/scd.2015.0112","journal-title":"Stem Cells Dev"},{"key":"162_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.stem.2007.10.008","volume":"1","author":"H Qian","year":"2007","unstructured":"Qian H, Buza-Vidas N, Hyland CD et al (2007) Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 1:671\u2013684. doi:\n                    10.1016\/j.stem.2007.10.008","journal-title":"Cell Stem Cell"},{"key":"162_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","volume":"1","author":"H Yoshihara","year":"2007","unstructured":"Yoshihara H, Arai F, Hosokawa K et al (2007) Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 1:685\u2013697. doi:\n                    10.1016\/j.stem.2007.10.020","journal-title":"Cell Stem Cell"},{"key":"162_CR38","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1084\/jem.20041992","volume":"201","author":"S Stier","year":"2005","unstructured":"Stier S, Ko Y, Forkert R et al (2005) Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 201:1781\u20131791. doi:\n                    10.1084\/jem.20041992","journal-title":"J Exp Med"},{"key":"162_CR39","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nature12612","volume":"502","author":"Y Kunisaki","year":"2013","unstructured":"Kunisaki Y, Bruns I, Scheiermann C et al (2013) Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 502:637\u2013643. doi:\n                    10.1038\/nature12612","journal-title":"Nature"},{"key":"162_CR40","volume-title":"Williams\u2019 hematology","author":"C Abboud","year":"2001","unstructured":"Abboud C, Lichtman M (2001) Williams\u2019 hematology, 6th edn. McGraw-Hil, New York","edition":"6"},{"key":"162_CR41","doi-asserted-by":"publisher","first-page":"e03696","DOI":"10.7554\/eLife.03696","volume":"3","author":"J Isern","year":"2014","unstructured":"Isern J, Garc\u00eda-Garc\u00eda A, Mart\u00edn AM et al (2014) The neural crest is a source of mesenchymal stem cells with specialized hematopoietic stem cell niche function. Elife 3:e03696. doi:\n                    10.7554\/eLife.03696","journal-title":"Elife"},{"key":"162_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nature09262","volume":"466","author":"S M\u00e9ndez-Ferrer","year":"2010","unstructured":"M\u00e9ndez-Ferrer S, Michurina TV, Ferraro F et al (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466:829\u2013834. doi:\n                    10.1038\/nature09262","journal-title":"Nature"},{"key":"162_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000251","author":"M Seshadri","year":"2016","unstructured":"Seshadri M, Qu C-K (2016) Microenvironmental regulation of hematopoietic stem cells and its implications in leukemogenesis. Curr Opin Hematol. doi:\n                    10.1097\/MOH.0000000000000251","journal-title":"Curr Opin Hematol"},{"key":"162_CR44","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2005.05.026","volume":"121","author":"MJ Kiel","year":"2005","unstructured":"Kiel MJ, Yilmaz OH, Iwashita T et al (2005) SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121:1109\u20131121. doi:\n                    10.1016\/j.cell.2005.05.026","journal-title":"Cell"},{"key":"162_CR45","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1172\/JCI43414","volume":"121","author":"Y Shiozawa","year":"2011","unstructured":"Shiozawa Y, Pedersen EA, Havens AM et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Investig 121:1298\u20131312. doi:\n                    10.1172\/JCI43414","journal-title":"J Clin Investig"},{"key":"162_CR46","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/MOH.0000000000000265","volume":"23","author":"VWC Yu","year":"2016","unstructured":"Yu VWC, Scadden DT (2016) Heterogeneity of the bone marrow niche. Curr Opin Hematol 23:331\u2013338. doi:\n                    10.1097\/MOH.0000000000000265","journal-title":"Curr Opin Hematol"},{"key":"162_CR47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","volume":"102","author":"BO Oyajobi","year":"2003","unstructured":"Oyajobi BO, Franchin G, Williams PJ et al (2003) Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102:311\u2013319. doi:\n                    10.1182\/blood-2002-12-3905","journal-title":"Blood"},{"key":"162_CR48","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1080\/10428190500175049","volume":"46","author":"E Terpos","year":"2005","unstructured":"Terpos E, Politou M, Viniou N, Rahemtulla A (2005) Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma 46:1699\u20131707. doi:\n                    10.1080\/10428190500175049","journal-title":"Leuk Lymphoma"},{"key":"162_CR49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1365-2141.2004.04864.x","volume":"125","author":"T Hashimoto","year":"2004","unstructured":"Hashimoto T, Abe M, Oshima T et al (2004) Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 125:38\u201341","journal-title":"Br J Haematol"},{"key":"162_CR50","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrc.2016.44","volume":"16","author":"PI Croucher","year":"2016","unstructured":"Croucher PI, McDonald MM, Martin TJ (2016) Bone metastasis: the importance of the neighborhood. Nat Rev Cancer 16:373\u2013386. doi:\n                    10.1038\/nrc.2016.44","journal-title":"Nat Rev Cancer"},{"key":"162_CR51","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","volume":"6","author":"MA Lawson","year":"2015","unstructured":"Lawson MA, McDonald MM, Kovacic NN et al (2015) Osteoclasts control re-activation of dormant myeloma cells by remodeling the endosteal niche. Nat Commun 6:8983. doi:\n                    10.1038\/ncomms9983","journal-title":"Nat Commun"},{"key":"162_CR52","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1182\/blood-2014-02-558007","volume":"124","author":"MR Reagan","year":"2014","unstructured":"Reagan MR, Mishima Y, Glavey SV et al (2014) Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood 124:3250\u20133259. doi:\n                    10.1182\/blood-2014-02-558007","journal-title":"Blood"},{"key":"162_CR53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12935-014-0132-6","volume":"14","author":"R Fu","year":"2014","unstructured":"Fu R, Liu H, Zhao S et al (2014) Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. Cancer Cell Int 14:132. doi:\n                    10.1186\/s12935-014-0132-6","journal-title":"Cancer Cell Int"},{"key":"162_CR54","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/leu.2011.381","volume":"26","author":"N Giuliani","year":"2012","unstructured":"Giuliani N, Ferretti M, Bolzoni M et al (2012) Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia 26:1391\u20131401. doi:\n                    10.1038\/leu.2011.381","journal-title":"Leukemia"},{"key":"162_CR55","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","volume":"8","author":"J Delgado-Calle","year":"2014","unstructured":"Delgado-Calle J, Bellido T, Roodman GD (2014) Role of osteocytes in multiple myeloma bone disease. Curr Opin Support Palliat Care 8:407\u2013413. doi:\n                    10.1097\/SPC.0000000000000090","journal-title":"Curr Opin Support Palliat Care"},{"key":"162_CR56","first-page":"266","volume":"15","author":"H Habibi","year":"2013","unstructured":"Habibi H, Abroun S, Hajifathali A et al (2013) Osteogenic inhibition in multiple myeloma. Cell J 15:266\u2013271","journal-title":"Cell J"},{"key":"162_CR57","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.celrep.2014.08.042","volume":"9","author":"AM Roccaro","year":"2014","unstructured":"Roccaro AM, Sacco A, Purschke WG et al (2014) SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep 9:118\u2013128. doi:\n                    10.1016\/j.celrep.2014.08.042","journal-title":"Cell Rep"},{"key":"162_CR58","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","volume":"113","author":"AK Azab","year":"2009","unstructured":"Azab AK, Runnels JM, Pitsillides C et al (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113:4341\u20134351. doi:\n                    10.1182\/blood-2008-10-186668","journal-title":"Blood"},{"key":"162_CR59","doi-asserted-by":"publisher","first-page":"e9870","DOI":"10.1371\/journal.pone.0009870","volume":"5","author":"K Takeuchi","year":"2010","unstructured":"Takeuchi K, Abe M, Hiasa M et al (2010) Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One 5:e9870. doi:\n                    10.1371\/journal.pone.0009870","journal-title":"PLoS One"},{"key":"162_CR60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2007-11-124164","volume":"112","author":"X Li","year":"2008","unstructured":"Li X, Pennisi A, Yaccoby S (2008) Role of decorin in the antimyeloma effects of osteoblasts. Blood 112:159\u2013168. doi:\n                    10.1182\/blood-2007-11-124164","journal-title":"Blood"},{"key":"162_CR61","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1182\/blood-2013-07-517219","volume":"124","author":"M Krevvata","year":"2014","unstructured":"Krevvata M, Silva BC, Manavalan JS et al (2014) Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood 124:2834\u20132846. doi:\n                    10.1182\/blood-2013-07-517219","journal-title":"Blood"},{"key":"162_CR62","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1182\/blood-2013-07-517136","volume":"123","author":"Z Chen","year":"2014","unstructured":"Chen Z, Orlowski RZ, Wang M et al (2014) Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123:2204\u20132208. doi:\n                    10.1182\/blood-2013-07-517136","journal-title":"Blood"},{"key":"162_CR63","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bone.2015.02.021","volume":"75","author":"MR Reagan","year":"2015","unstructured":"Reagan MR, Liaw L, Rosen CJ, Ghobrial IM (2015) Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone 75:161\u2013169. doi:\n                    10.1016\/j.bone.2015.02.021","journal-title":"Bone"},{"key":"162_CR64","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/10428190903503438","volume":"51","author":"S Yaccoby","year":"2010","unstructured":"Yaccoby S (2010) Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma 51:213\u2013220. doi:\n                    10.3109\/10428190903503438","journal-title":"Leuk Lymphoma"},{"key":"162_CR65","first-page":"192","volume":"91","author":"S Yaccoby","year":"2006","unstructured":"Yaccoby S, Wezeman MJ, Zangari M et al (2006) Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 91:192\u2013199","journal-title":"Haematologica"},{"key":"162_CR66","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1158\/0008-5472.CAN-12-2280","volume":"73","author":"BJ Schmiedel","year":"2013","unstructured":"Schmiedel BJ, Scheible CA, Nuebling T et al (2013) RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. Cancer Res 73:683\u2013694. doi:\n                    10.1158\/0008-5472.CAN-12-2280","journal-title":"Cancer Res"},{"key":"162_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2789","author":"H Eda","year":"2016","unstructured":"Eda H, Santo L, Wein MN et al (2016) regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease. J Bone Miner Res. doi:\n                    10.1002\/jbmr.2789","journal-title":"J Bone Miner Res"},{"key":"162_CR68","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.1182\/blood-2011-04-351437","volume":"118","author":"AC Ng","year":"2011","unstructured":"Ng AC, Khosla S, Charatcharoenwitthaya N et al (2011) Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1\u03b1 levels in patients with MGUS. Blood 118:6529\u20136534. doi:\n                    10.1182\/blood-2011-04-351437","journal-title":"Blood"},{"key":"162_CR69","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/jbmr.2387","volume":"29","author":"MT Drake","year":"2014","unstructured":"Drake MT (2014) Unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res 29:2529\u20132533. doi:\n                    10.1002\/jbmr.2387","journal-title":"J Bone Miner Res"},{"key":"162_CR70","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.leu.2404658","volume":"21","author":"J Caers","year":"2007","unstructured":"Caers J, Deleu S, Belaid Z et al (2007) Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia 21:1580\u20131584. doi:\n                    10.1038\/sj.leu.2404658","journal-title":"Leukemia"},{"key":"162_CR71","doi-asserted-by":"publisher","first-page":"34329","DOI":"10.18632\/oncotarget.6020","volume":"6","author":"Z Liu","year":"2015","unstructured":"Liu Z, Xu J, He J et al (2015) Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget 6:34329\u201334341. doi:\n                    10.18632\/oncotarget.6020","journal-title":"Oncotarget"},{"key":"162_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.112","author":"EA Medina","year":"2014","unstructured":"Medina EA, Oberheu K, Polusani SR et al (2014) PKA\/AMPK signaling in relation to adiponectin\u2019s antiproliferative effect on multiple myeloma cells. Leukemia. doi:\n                    10.1038\/leu.2014.112","journal-title":"Leukemia"},{"key":"162_CR73","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/blood-2012-06-438606","volume":"120","author":"JN Hofmann","year":"2012","unstructured":"Hofmann JN, Liao LM, Pollak MN et al (2012) A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood 120:4418\u20134420. doi:\n                    10.1182\/blood-2012-06-438606","journal-title":"Blood"},{"key":"162_CR74","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2406","author":"JN Hofmann","year":"2016","unstructured":"Hofmann JN, Birmann BM, Teras LR et al (2016) Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals. Cancer Res. doi:\n                    10.1158\/0008-5472.CAN-15-2406","journal-title":"Cancer Res"},{"key":"162_CR75","doi-asserted-by":"publisher","first-page":"5872","DOI":"10.1182\/blood-2011-01-330407","volume":"118","author":"JA Fowler","year":"2011","unstructured":"Fowler JA, Lwin ST, Drake MT et al (2011) Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood 118:5872\u20135882. doi:\n                    10.1182\/blood-2011-01-330407","journal-title":"Blood"},{"key":"162_CR76","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1210\/er.2011-1015","volume":"33","author":"M Dalamaga","year":"2012","unstructured":"Dalamaga M, Diakopoulos KN, Mantzoros CS (2012) The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33:547\u2013594. doi:\n                    10.1210\/er.2011-1015","journal-title":"Endocr Rev"},{"key":"162_CR77","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1006\/bbrc.1999.0255","volume":"257","author":"Y Arita","year":"1999","unstructured":"Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79\u201383. doi:\n                    10.1006\/bbrc.1999.0255","journal-title":"Biochem Biophys Res Commun"},{"key":"162_CR78","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/aje\/kws295","volume":"177","author":"JN Hofmann","year":"2013","unstructured":"Hofmann JN, Moore SC, Lim U et al (2013) Body mass index and physical activity at different ages and risk of multiple myeloma in the NIH-AARP diet and health study. Am J Epidemiol 177:776\u2013786. doi:\n                    10.1093\/aje\/kws295","journal-title":"Am J Epidemiol"},{"key":"162_CR79","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/bmt.2014.63","volume":"49","author":"DM Greenfield","year":"2014","unstructured":"Greenfield DM, Boland E, Ezaydi Y et al (2014) Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. Bone Marrow Transplant 49:907\u2013912. doi:\n                    10.1038\/bmt.2014.63","journal-title":"Bone Marrow Transplant"},{"key":"162_CR80","doi-asserted-by":"publisher","first-page":"e0134290","DOI":"10.1371\/journal.pone.0134290","volume":"10","author":"MJ Abbott","year":"2015","unstructured":"Abbott MJ, Roth TM, Ho L et al (2015) Negative skeletal effects of locally produced adiponectin. PLoS One 10:e0134290. doi:\n                    10.1371\/journal.pone.0134290","journal-title":"PLoS One"},{"key":"162_CR81","doi-asserted-by":"publisher","first-page":"24946","DOI":"10.3390\/ijms161024946","volume":"16","author":"H Hu","year":"2015","unstructured":"Hu H, Pu Y, Lu S et al (2015) The osteogenesis effect and underlying mechanisms of local delivery of gAPN in extraction sockets of beagle dogs. Int J Mol Sci 16:24946\u201324964. doi:\n                    10.3390\/ijms161024946","journal-title":"Int J Mol Sci"},{"key":"162_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00067","author":"C Falank","year":"2016","unstructured":"Falank C, Fairfield H, Reagan M (2016) Signaling mechanisms between bone marrow adipose tissue and multiple myeloma cells. Front Endocrinol (Lausanne). doi:\n                    10.3389\/fendo.2016.00067","journal-title":"Front Endocrinol (Lausanne)"},{"key":"162_CR83","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1158\/0008-5472.CAN-11-2067","volume":"72","author":"JA Fowler","year":"2012","unstructured":"Fowler JA, Mundy GR, Lwin ST, Edwards CM (2012) Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res 72:2183\u20132189. doi:\n                    10.1158\/0008-5472.CAN-11-2067","journal-title":"Cancer Res"},{"key":"162_CR84","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/1078-0432.CCR-11-2212","volume":"18","author":"MR Reagan","year":"2012","unstructured":"Reagan MR, Ghobrial IM (2012) Multiple myeloma-mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res 18:342\u2013349. doi:\n                    10.1158\/1078-0432.CCR-11-2212","journal-title":"Clin Cancer Res"},{"key":"162_CR85","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1172\/JCI66517","volume":"123","author":"AM Roccaro","year":"2013","unstructured":"Roccaro AM, Sacco A, Maiso P et al (2013) BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Investig 123:1542\u20131555. doi:\n                    10.1172\/JCI66517","journal-title":"J Clin Investig"},{"key":"162_CR86","doi-asserted-by":"publisher","first-page":"e17336","DOI":"10.1371\/journal.pone.0017336","volume":"6","author":"H Nyangoga","year":"2011","unstructured":"Nyangoga H, Mercier P, Libouban H et al (2011) Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (MicroCT). PLoS One 6:e17336. doi:\n                    10.1371\/journal.pone.0017336","journal-title":"PLoS One"},{"key":"162_CR87","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00432-015-1952-z","volume":"141","author":"MG Alexandrakis","year":"2015","unstructured":"Alexandrakis MG, Neonakis IK, Pappa CA et al (2015) Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma. J Cancer Res Clin Oncol 141:1503\u20131509. doi:\n                    10.1007\/s00432-015-1952-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"162_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.3","author":"M Moschetta","year":"2016","unstructured":"Moschetta M, Mishima Y, Kawano Y et al (2016) Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia. doi:\n                    10.1038\/leu.2016.3","journal-title":"Leukemia"},{"key":"162_CR89","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","volume":"110","author":"N Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S et al (2007) The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110:334\u2013338. doi:\n                    10.1182\/blood-2006-11-059188","journal-title":"Blood"},{"key":"162_CR90","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.3747\/co.20.1055","volume":"20","author":"A Avil\u00e9s","year":"2013","unstructured":"Avil\u00e9s A, Neri N, Huerta-Guzm\u00e1n J, Nambo MJ (2013) Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Curr Oncol 20:e13\u2013e20. doi:\n                    10.3747\/co.20.1055","journal-title":"Curr Oncol"},{"key":"162_CR91","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","volume":"19","author":"GJ Morgan","year":"2013","unstructured":"Morgan GJ, Davies FE, Gregory WM et al (2013) Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 19:6030\u20136038. doi:\n                    10.1158\/1078-0432.CCR-12-3211","journal-title":"Clin Cancer Res"},{"key":"162_CR92","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fphar.2015.00226","volume":"6","author":"D Tibullo","year":"2015","unstructured":"Tibullo D, Di Rosa M, Giallongo C et al (2015) Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. Front Pharmacol 6:226. doi:\n                    10.3389\/fphar.2015.00226","journal-title":"Front Pharmacol"},{"key":"162_CR93","doi-asserted-by":"publisher","first-page":"16918","DOI":"10.1074\/jbc.M115.663963","volume":"290","author":"Y Yang","year":"2015","unstructured":"Yang Y, Blair HC, Shapiro IM, Wang B (2015) The proteasome inhibitor carfilzomib suppresses parathyroid hormone-induced osteoclastogenesis through a RANKL-mediated signaling pathway. J Biol Chem 290:16918\u201316928. doi:\n                    10.1074\/jbc.M115.663963","journal-title":"J Biol Chem"},{"key":"162_CR94","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-016-0428-7","volume":"11","author":"SM Hoy","year":"2016","unstructured":"Hoy SM (2016) Carfilzomib triple combination therapy: a review in relapsed multiple myeloma. Target Oncol 11:255\u2013262. doi:\n                    10.1007\/s11523-016-0428-7","journal-title":"Target Oncol"},{"key":"162_CR95","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/DDDT.S93602","volume":"10","author":"B Muz","year":"2016","unstructured":"Muz B, Ghazarian RN, Ou M et al (2016) Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Dev Ther 10:217\u2013226. doi:\n                    10.2147\/DDDT.S93602","journal-title":"Drug Des Dev Ther"},{"key":"162_CR96","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","volume":"107","author":"G Anderson","year":"2006","unstructured":"Anderson G, Gries M, Kurihara N et al (2006) Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107:3098\u20133105. doi:\n                    10.1182\/blood-2005-08-3450","journal-title":"Blood"},{"key":"162_CR97","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P et al (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14:1055\u20131066. doi:\n                    10.1016\/S1470-2045(13)70380-2","journal-title":"Lancet Oncol"},{"key":"162_CR98","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.exphem.2014.03.005","volume":"42","author":"A Bolomsky","year":"2014","unstructured":"Bolomsky A, Schreder M, Mei\u00dfner T et al (2014) Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro. Exp Hematol 42:516\u2013525. doi:\n                    10.1016\/j.exphem.2014.03.005","journal-title":"Exp Hematol"},{"key":"162_CR99","first-page":"129","volume":"33","author":"S Munemasa","year":"2008","unstructured":"Munemasa S, Sakai A, Kuroda Y et al (2008) Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol 33:129\u2013136","journal-title":"Int J Oncol"},{"key":"162_CR100","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1038\/bcj.2015.96","volume":"6","author":"N Raje","year":"2016","unstructured":"Raje N, Vadhan-Raj S, Willenbacher W et al (2016) Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer J 6:e378. doi:\n                    10.1038\/bcj.2015.96","journal-title":"Blood Cancer J"},{"key":"162_CR101","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/bonekey.2015.113","volume":"4","author":"E Terpos","year":"2015","unstructured":"Terpos E, Confavreux CB, Cl\u00e9zardin P (2015) Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. Bonekey Rep 4:744. doi:\n                    10.1038\/bonekey.2015.113","journal-title":"Bonekey Rep"},{"key":"162_CR102","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1073\/pnas.0911929107","volume":"107","author":"S Vallet","year":"2010","unstructured":"Vallet S, Mukherjee S, Vaghela N et al (2010) Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 107:5124\u20135129. doi:\n                    10.1073\/pnas.0911929107","journal-title":"Proc Natl Acad Sci USA"},{"key":"162_CR103","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/annonc\/mds068","volume":"23","author":"E Terpos","year":"2012","unstructured":"Terpos E, Kastritis E, Christoulas D et al (2012) Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol 23:2681\u20132686. doi:\n                    10.1093\/annonc\/mds068","journal-title":"Ann Oncol"},{"key":"162_CR104","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/jbmr.142","volume":"25","author":"AD Chantry","year":"2010","unstructured":"Chantry AD, Heath D, Mulivor AW et al (2010) Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res 25:2633\u20132646. doi:\n                    10.1002\/jbmr.142","journal-title":"J Bone Miner Res"},{"key":"162_CR105","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12307-011-0090-7","volume":"4","author":"S Vallet","year":"2011","unstructured":"Vallet S, Raje N (2011) Bone anabolic agents for the treatment of multiple myeloma. Cancer Microenviron Off J Int Cancer Microenviron Soc 4:339\u2013349. doi:\n                    10.1007\/s12307-011-0090-7","journal-title":"Cancer Microenviron Off J Int Cancer Microenviron Soc"},{"key":"162_CR106","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/bjh.13056","volume":"167","author":"SP Iyer","year":"2014","unstructured":"Iyer SP, Beck JT, Stewart AK et al (2014) A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 167:366\u2013375. doi:\n                    10.1111\/bjh.13056","journal-title":"Br J Haematol"},{"key":"162_CR107","doi-asserted-by":"publisher","first-page":"e74191","DOI":"10.1371\/journal.pone.0074191","volume":"8","author":"B Hu","year":"2013","unstructured":"Hu B, Chen Y, Usmani SZ et al (2013) Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One 8:e74191. doi:\n                    10.1371\/journal.pone.0074191","journal-title":"PLoS One"},{"key":"162_CR108","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","volume":"18","author":"PI Croucher","year":"2003","unstructured":"Croucher PI, De Hendrik R, Perry MJ et al (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18:482\u2013492. doi:\n                    10.1359\/jbmr.2003.18.3.482","journal-title":"J Bone Miner Res"},{"key":"162_CR109","first-page":"287","volume":"63","author":"K Vanderkerken","year":"2003","unstructured":"Vanderkerken K, De Leenheer E, Shipman C et al (2003) Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 63:287\u2013289","journal-title":"Cancer Res"},{"key":"162_CR110","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)61032-7","volume":"386","author":"R Coleman","year":"2015","unstructured":"Coleman R, Powles T, Paterson A et al (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:1353\u20131361. doi:\n                    10.1016\/S0140-6736(15)60908-4","journal-title":"Lancet"},{"key":"162_CR111","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (Lond Engl) 379:39\u201346. doi:\n                    10.1016\/S0140-6736(11)61226-9","journal-title":"Lancet (Lond Engl)"},{"key":"162_CR112","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","volume":"109","author":"S Yaccoby","year":"2007","unstructured":"Yaccoby S, Ling W, Zhan F et al (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109:2106\u20132111. doi:\n                    10.1182\/blood-2006-09-047712","journal-title":"Blood"},{"key":"162_CR113","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.bone.2013.01.012","volume":"53","author":"S Pozzi","year":"2013","unstructured":"Pozzi S, Fulciniti M, Yan H et al (2013) In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone 53:487\u2013496. doi:\n                    10.1016\/j.bone.2013.01.012","journal-title":"Bone"},{"key":"162_CR114","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Tassone P, Hideshima T et al (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371\u2013379. doi:\n                    10.1182\/blood-2008-11-191577","journal-title":"Blood"},{"key":"162_CR115","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1359\/jbmr.081104","volume":"24","author":"DJ Heath","year":"2009","unstructured":"Heath DJ, Chantry AD, Buckle CH et al (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24:425\u2013436. doi:\n                    10.1359\/jbmr.081104","journal-title":"J Bone Miner Res"},{"key":"162_CR116","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bone.2014.03.044","volume":"64","author":"M Styner","year":"2014","unstructured":"Styner M, Thompson WR, Galior K et al (2014) Bone marrow fat accumulation accelerated by high fat diet is suppressed by exercise. Bone 64:39\u201346. doi:\n                    10.1016\/j.bone.2014.03.044","journal-title":"Bone"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-016-0162-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-016-0162-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-016-0162-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-016-0162-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T05:29:42Z","timestamp":1589693382000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-016-0162-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,24]]},"references-count":116,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1007\/s00223-016-0162-2","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,24]]},"assertion":[{"value":"9 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michelle McDonald, Heather Fairfield, Carolyne Falank, Michaela R. Reagan are no potential conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}